High-sensitivity troponin I in persistent atrial fibrillation – relation to NT-proBNP and markers of inflammation and haemostasis

References

• Björck S, Palaszewski B, Friberg L, et al. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44:3103–3108.
   PubMed Web of Science ®Google Scholar
• Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4:e001486.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Lindbäck J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37:1582–1590.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Lindbäck J, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018;39:477–485.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387:2302–2311.
   PubMed Web of Science ®Google Scholar
• White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011;57:2406–2408.
   PubMed Web of Science ®Google Scholar
• Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373:155–166.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Sekiguchi A, Iwasaki YK, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J. 2010;74:262–270.
   PubMed Web of Science ®Google Scholar
• Roldán V, Marín F, Díaz J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012;10:1500–1507.
   PubMed Web of Science ®Google Scholar
• Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007;120:85–91.
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemos Thromb. 2003;33:4–15.
   PubMed Web of Science ®Google Scholar
• Christersson C, Wallentin L, Andersson U, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial. J Thromb Haemost. 2014;12:1401–1412.
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Draxler DF, Gruber SC, et al. Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillation. J Thromb Haemost. 2013;11:1069–1077.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy S, Khoo CW, Lim HS, et al. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a ‘real-world’ community cohort of patients with atrial fibrillation. Eur J Clin Invest. 2013;43:1032–1038.
   PubMed Web of Science ®Google Scholar
• Willeit K, Pechlaner R, Willeit P, et al. Association between vascular cell adhesion molecule 1 and atrial fibrillation. JAMA Cardiol. 2017;2:516–523.
   PubMed Web of Science ®Google Scholar
• Han W, Fu S, Wei N, et al. Nitric oxide overproduction derived from inducible nitric oxide synthase increases cardiomyocyte apoptosis in human atrial fibrillation. Int J Cardiol. 2008;130:165–173.
   PubMed Web of Science ®Google Scholar
• Ford I, Shah AS, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016;68:2719–2728.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125:1605–1616.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Siegbahn A, Andersson U, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;129:625–634.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Aulin J, Andersson U, et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016;102:508–517.
   PubMed Web of Science ®Google Scholar
• Horjen AW, Ulimoen SR, Enger S, et al. Impact of atrial fibrillation on levels of high-sensitivity troponin I in a 75-year-old population. Scand J Clin Lab Invest. 2015;75:308–313.
   PubMed Web of Science ®Google Scholar
• Ulimoen SR, Enger S, Pripp AH, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J. 2014;35:517–524.
   PubMed Web of Science ®Google Scholar
• Horjen AW, Ulimoen SR, Enger S, et al. Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing. BMC Cardiovasc Disord. 2016;16:79.
   PubMed Web of Science ®Google Scholar
• Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000;31:828–833.
   PubMed Web of Science ®Google Scholar